PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE Nov 13, 2023 08:00AM
US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM Aug 11, 2023 09:58AM
PYC Therapeutics Announces Upcoming Poster Presentations Highlighting Preclinical Data from its Ocular and Neurologic Development Programs at TIDES USA and OTS 2021 Sep 21, 2021 07:00AM
PYC Therapeutics Invited to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sep 15, 2021 07:00AM
PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board Aug 17, 2021 07:00AM


Aug 11, 2021 07:00AM PYC Therapeutics to Host Quarterly Investor Call on August 17 at 9 a.m. AWST | 11 a.m. AEST
Aug 3, 2021 07:00AM PYC Therapeutics Announces Participation in Upcoming Investor Conferences
Jul 28, 2021 07:00AM PYC Therapeutics Highlights Advancement of Ocular and CNS Development Programs And Continued U.S. Expansion in Second Quarter 2021 Update
Jun 29, 2021 07:00AM PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy
Jun 15, 2021 07:00AM PYC Therapeutics Establishing New U.S. Headquarters in San Diego, Announces Residency at Johnson & Johnson Innovation, JLABS
May 26, 2021 07:00AM PYC Therapeutics to Participate in the Evercore ISI GenomeRx Emerging Therapeutic Company Day
May 4, 2021 07:00AM PYC Therapeutics Announces Two Poster Presentations at Association for Research in Vision and Opthalmology (ARVO) 2021 Annual Meeting
Apr 30, 2021 07:00AM PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Update
Apr 12, 2021 07:00AM PYC Therapeutics Announces Preclinical Data Demonstrating Superior PPMO Delivery to the Brain
Apr 6, 2021 07:00AM PYC Therapeutics to Host Quarterly Investor Call on April 15th 8:00am AWST | 10am AEST
Mar 29, 2021 07:00AM PYC Therapeutics Appoints U.S. Biopharma Executive Jason Haddock to its Board of Directors
Mar 22, 2021 07:00AM PYC Therapeutics Invited to Participate in the SVB Leerink Biopharma Private Company Connect
Mar 17, 2021 07:00AM PYC Therapeutics Appoints U.S. Biotech Veteran Michael Rosenblatt, MD, to its Board of Directors
Mar 2, 2021 07:00AM PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - A First for Any RP11 Treatment To-Date
Feb 23, 2021 07:00AM PYC Therapeutics Expands U.S. Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer
Feb 22, 2021 07:00AM PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives
Feb 11, 2021 07:00AM PYC Therapeutics Invited to Participate in RNA Panel at 2021 BIO CEO & Investor Digital Conference